A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Longboard Pharmaceuticals
- Study ID
- NCT06908226
- Phase
- PHASE3
- Status
- Enrolling By Invitation
Conditions
- Developmental and Epileptic Encephalopathy
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - 66 Years
- Healthy Volunteers
- Not accepted
Interventions
- LP352 — DRUGLP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube.
Study Details
This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.
Key Dates
- Start date
- Feb 12, 2025
- Status verified
- Dec 2025
- Primary completion
- Nov 11, 2027
- Completion
- Dec 17, 2027
Study Design
- Enrollment
- 324 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: LP352Participants will be titrated up to highest tolerated dose of LP352 during the Titration period (Visit 1 - Visit 3), followed by maintenance period (Visit 4 - Visit 14) and then taper/down titration period (Visit 15 - Visit 17).
Primary Outcome Measure
Number of participants reporting Treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) and AEs leading to discontinuation [ Time Frame: Up to 61 Weeks ]
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Arkansas Children's Hospital - PIN | Little Rock | Arkansas | 72202-3500 | - |
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90095 | - |
| NW FL Clinical Research Group, LLC | Gulf Breeze | Florida | 32561-4458 | - |
| Research Institute of Orlando LLC | Orlando | Florida | 32806-5411 | - |
| Pediatric Epilepsy and Neurology Specialists | Tampa | Florida | 33609-4181 | - |
| Mid-Atlantic Epilepsy and Sleep Center | Bethesda | Maryland | 20817-1809 | - |
| Institute of Neurology and Neurosurgery at Saint Barnabas, LLC | Livingston | New Jersey | 07039-5817 | - |
| Northeast Regional Epilepsy Group - Morristown - 310 Madison Ave | Morristown | New Jersey | 07960 | - |
| The University of Texas Medical School at Houston | Houston | Texas | 77030-3000 | - |
Find similar trials in Little Rock, AR
By research site
Arkansas Children's Hospital - PIN· Little Rock, ARDavid Geffen School of Medicine at UCLA· Los Angeles, CANW FL Clinical Research Group, LLC· Gulf Breeze, FLResearch Institute of Orlando LLC· Orlando, FLPediatric Epilepsy and Neurology Specialists· Tampa, FLMid-Atlantic Epilepsy and Sleep Center· Bethesda, MD
Related Studies
- A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)PHASE3 · Recruiting · Longboard Pharmaceuticals · Little Rock, Arkansas